<DOC>
	<DOCNO>NCT01392560</DOCNO>
	<brief_summary>This open-label study aim evaluate impact BI 10773 treatment glomerular filtration rate control condition euglycaemia hyperglycaemia subject type 1 diabetes mellitus without renal hyperfiltration characterize safety efficacy BI 10773 25 mg QD add-on therapy insulin subject .</brief_summary>
	<brief_title>Safety Efficacy Empagliflozin ( BI 10773 ) Type 1 Diabetes Mellitus Patients With Without Renal Hyperfiltration</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female subject 18 year age old diagnose type 1 diabetes mellitus 2 . Glycated hemoglobin ( HbA1C ) 6.5 % 11.0 % estimate glomerular filtration rate ( eGFR ) great equal 60 ml/min/1.73mÂ² screen 3 . Subjects must either experienced insulin pump user multiple daily injection type insulin Exclusion criterion : 1 . Evidence macroalbuminuria leukocyte positive urinalysis screen 2 . Any concomitant medication know interfere reninangiotensinaldosterone system ( RAAS ) activity treatment drug reduce blood glucose insulin 3 . History macrovascular disease disease would interfere trial participation ongoing clinical condition would jeopardize subject safety study compliance base investigator judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>